AnaptysBio, Inc. (AN6.F)

19,70 -0,20 (-1,01%) Ab 08:05AM CEST. Markt geöffnet.

AnaptysBio, Inc.

10770 Wateridge Circle
Suite 210
San Diego, CA 92121-5801
United States
858 362 6295
https://www.anaptysbio.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 117

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Daniel R. Faga	President, CEO & Director	2,35M	N/A	1980
Mr. Eric J. Loumeau	Chief Legal Officer	674,37k	N/A	1963
Dr. Paul F. Lizzul FAAD, M.B.A., M.D., M.P.H., Ph.D.	Chief Medical Officer	690,13k	N/A	1975
Mr. Dennis M. Mulroy	Chief Financial Officer	419,2k	N/A	1955
Ms. Beth Mueller	Senior Vice President of Human Resources	N/A	N/A	N/A
Dr. Martin Dahl Ph.D.	Senior Vice President of Research	N/A	N/A	N/A
Mr. Benjamin Stone	Chief Business Officer	N/A	N/A	N/A
Mr. Douglas A. Rich M.B.A.	Senior Vice President of CMC	N/A	N/A	1969
Ms. Monique Da Silva	Senior Vice President of Corporate Affairs	N/A	N/A	N/A
Ms. Priya Raina	Senior Vice President of Clinical Operations	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in EUR.

Beschreibung

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.

Corporate Governance

AnaptysBio, Inc.s ISS Governance QualityScore, Stand 1. April 2024, lautet 10. Die grundlegenden Scores sind Audit: 9, Vorstand: 9, Shareholderrechte: 8, Kompensation: 10.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.